What I'm Working On · Updated Monthly
Now.
A standing snapshot of what's active. Updated monthly. The /now page convention from Derek Sivers.
Targeted Osmotic Lysis (TOL) is investigational. It has not been approved by the FDA for any indication. It is not available as a treatment. Exosome and mesenchymal stem cell-derived extracellular vesicle products are not approved by the FDA for any indication. Content on this page is educational and describes published scientific literature. It does not describe an available treatment, it does not report results in patients, and it does not offer access to any therapy.
Currently working on.
- Now
The
351(a) BLA pathway for mesenchymal exosomesPre-IND submission preparation, CMC documentation strategy, and INTERACT meeting positioning for Wharton's jelly mesenchymal stem cell exosome biologics on the FDA biologics pathway.
- Now
Targeted Osmotic Lysis clinical positioning
Working with an academic medical foundation to advance the TOL platform. TOL is investigational. It has not been approved by the FDA for any indication and it is not available as a treatment.
- Now
The Hillman Letter publication schedule
Weekly long-form essays on FDA regulatory strategy, frontier therapeutics, and capital decisions. Subscribe at The Hillman Letter.
- Now
Expert witness retentions
Active engagements across FDA, HIPAA, AKS, Stark, and OIG matters. Plaintiff and defense counsel. Dallas and nationwide.
- Now
SMU scholarship and grant cohorts
Selection committee work for the Andrew Hillman Scholarship for Entrepreneurs and the Andrew Hillman Grant for Biotech at SMU.